Hikma Launches Long-Awaited US Advair Rival

Competes With Viatris’ Wixela Inhub, But Not In All Strengths

Hikma has gained FDA approval for and launched its long-in-development generic version of Advair Diskus. The milestone puts it in direct competition with Viatris’ Wixela Inhub version that was launched almost two years ago, in three presentations compared to Hikma’s two.

Video Game Pixel Art Two Players
A second player has entered the market for generic Advair • Source: Shutterstock

After a number of development challenges and setbacks, Hikma has now received US Food and Drug Administration approval for and launched its generic version of GlaxoSmithKline’s Advair Diskus (fluticasone/salmeterol) in the US.

The launch – which comes slightly earlier than expected following a recent FDA complete response letter – puts Hikma in...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Products

More from Generics Bulletin